CAL
AVIR icon

Capital Advisors Ltd’s Atea Pharmaceuticals AVIR Stock Holding History

Capital Advisors Ltd’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,641
Closed -$7K – 1372
2024
Q1 		$7K Buy
+1,641
New +$6.42K ﹤0.01% 781
2022
Q4 		– Sell
-22
Closed – – 1215
2022
Q3 		$0 Buy
22
+20
+1,000% +$153 ﹤0.01% 1237
2022
Q2 		$0 Sell
2
-6
-75% -$41 ﹤0.01% 1001
2022
Q1 		$0 Buy
+8
New +$54 ﹤0.01% 905

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Capital Advisors Ltd's AVIR Position: Q2 2024 in Review

Capital Advisors Ltd sold out of Atea Pharmaceuticals (AVIR) in Q2 2024, closing a stake of 1,641 shares — an estimated $7K sold.

Capital Advisors Ltd first reported a position in AVIR in Q1 2022 and held it in 4 quarters. The position peaked at $7K in Q1 2024. 105 funds tracked by Wall St. Rank hold AVIR as of Q2 2024.

  • Capital Advisors Ltd reported no remaining Atea Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Capital Advisors Ltd sold 1,641 Atea Pharmaceuticals shares in Q2 2024, an estimated $7K.
  • Capital Advisors Ltd first reported a position in Atea Pharmaceuticals in Q1 2022 and held it in 4 quarters.
  • Capital Advisors Ltd's Atea Pharmaceuticals position peaked at $7K in Q1 2024.
  • 105 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2024.

Based on Capital Advisors Ltd's 13F filing for Q2 2024, filed 25 Jul 2024.